Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 567 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Obesity Type 2 Diabetes Mellitus Clear all
Recruiting Phase 2 Interventional

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

NCT07589608
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Macupatide, Eloralintide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 13, 2026, 9:46 PM EDT
Completed Not applicable Interventional Results available

Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth

NCT00413335
View directory record Official record
Conditions
Obesity, Impaired Glucose Tolerance, Type 2 Diabetes Mellitus
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
10 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 13, 2026, 9:46 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of the Thrive AI Health App on Lifestyle Behaviors and Quality of Life

NCT07376655
View directory record Official record
Conditions
Diabetes Type 2, Overweight or Obesity
Interventions
App
Behavioral
Lead sponsor
Yale University
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 13, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases

NCT00001723
View directory record Official record
Conditions
Diabetes Mellitus, Hypertension, Metabolic Disease, Obesity, Sleep Apnea Syndrome
Interventions
Orlistat, Placebo
Drug
Lead sponsor
Jack Yanovski
NIH
Eligibility
12 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 13, 2026, 9:46 PM EDT
Completed Phase 4 Interventional

A Very High Fiber Diet Versus a Low-carbohydrate Diet for Weight Loss

NCT01051674
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
High fiber vs. low-carbohydrate diets
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Oct 13, 2026, 9:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Changes in Insulin Sensitivity After Weight Loss

NCT00627484
View directory record Official record
Conditions
Obesity, Type 2 Diabetes Mellitus, Insulin Resistance
Interventions
Gastric bypass, Gastric banding, Sleeve gastrectomy, Very low calorie diet
Procedure · Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 13, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

NCT03235050
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose, Placebo, Liraglutide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 13, 2026, 9:46 PM EDT
Terminated Phase 2 Interventional Results available

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

NCT03152552
View directory record Official record
Conditions
Diabetes Mellitus and Heart Failure
Interventions
LIK066, Placebo, Empagliflozin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
21
States / cities
Huntsville, Alabama • Carmichael, California • Concord, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 13, 2026, 9:46 PM EDT
Terminated Phase 4 Interventional Results available

CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes

NCT02912455
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
canagliflozin, Placebo (for canagliflozin)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
20 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 13, 2026, 9:46 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Circadian Intervention to Improve Cardiometabolic Health

NCT05943626
View directory record Official record
Conditions
Cardiometabolic Syndrome, Type 2 Diabetes, Sleep, Time Restricted Feeding, Lifestyle Factors, Overweight and Obesity, Insulin Sensitivity, Eating Habit, Sleep Hygiene
Interventions
Circadian Intervention
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 13, 2026, 9:46 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin

NCT01686828
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen Deficiency, Metabolic Disease
Interventions
Acyline, Testosterone 1.62% gel, Letrozole, Placebo gel (for Testosterone 1.62% gel), Placebo pill (for Letrozole)
Drug
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 13, 2026, 9:46 PM EDT
Active, not recruiting Phase 2 Interventional

Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM

NCT06005012
View directory record Official record
Conditions
Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 79 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 13, 2026, 9:46 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Extracellular Vesicles, Insulin Action, and Exercise

NCT06546085
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Exercise
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
30 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
3
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 13, 2026, 9:46 PM EDT
Completed Phase 2 Interventional

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

NCT05536804
View directory record Official record
Conditions
Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Northridge, California • Aurora, Colorado • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 13, 2026, 9:46 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

NCT05762471
View directory record Official record
Conditions
Overweight or Obesity, Type2 Diabetes Mellitus
Interventions
GSBR-1290, Placebo
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Anaheim, California • Chula Vista, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 13, 2026, 9:46 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

NCT05890950
View directory record Official record
Conditions
Obesity, Type 2 Diabetes Mellitus in Obese
Interventions
K-757 and K-833, Matching placebo to K-757 and K-833
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 13, 2026, 9:46 PM EDT
Completed Phase 1Phase 2 Interventional

Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes

NCT03620773
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity, Bariatric Surgery Candidate, Nephropathy, Diabetic Kidney Disease, Diabetes Mellitus, Type 2, Diabetes Mellitus, Diabetes Complications, Weight Loss, Diabetic Nephropathies, Adolescent Obesity, Pediatric Obesity
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 mg/mL, Vertical Sleeve Gastrectomy, Renal Biopsy
Drug · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 13, 2026, 9:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth

NCT00536250
View directory record Official record
Conditions
Impaired Glucose Tolerance, Pre-diabetes, Childhood Obesity, Insulin Resistance, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
8 Years to 22 Years
Enrollment
255 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 13, 2026, 9:46 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Community Based DPP Program for Hispanic/Latino Females

NCT04052815
View directory record Official record
Conditions
Pre Diabetes, Obesity
Interventions
Diabetes prevention program culturally tailored
Behavioral
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 13, 2026, 9:46 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Molecular and Clinical Profile of Diabetes Mellitus and Its Complications

NCT01105858
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetic Nephropathy, Obesity
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 99 Years
Enrollment
2,310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 13, 2026, 9:46 PM EDT
Completed Phase 1 Interventional Results available

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

NCT01673178
View directory record Official record
Conditions
Diabetes Melliuts, Type 2
Interventions
Placebo, 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023, 150 mg PF-05231023
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
17
States / cities
Anaheim, California • Chula Vista, California • Walnut Creek, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 13, 2026, 9:46 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Household Participants

NCT06590649
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension, Dyslipidemias, Overweight and Obesity
Interventions
Household-level effects
Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Honolulu, Hawaii • Kapolei, Hawaii
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 13, 2026, 9:46 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

NCT06858839
View directory record Official record
Conditions
Obesity
Interventions
Maridebart Cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
3,853 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
74
States / cities
Anniston, Alabama • Daphne, Alabama • Mobile, Alabama + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 13, 2026, 9:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose

NCT04973111
View directory record Official record
Conditions
Diabetes
Interventions
CT-868 as SC Injection, Placebo as SC Injection, Active Comparator as SC Injection
Drug
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 13, 2026, 9:46 PM EDT